RxDoctor Payments Data

Lindsay Conlisk, PA

Physician Assistant · Darby, PANPI 1780306746

Payments from drug & device makers

$3,076in general payments, 2019–2025

Across 112 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$972
  • Sumitomo Pharma America, Inc.$584
  • Astellas Pharma US Inc$285
  • Bayer$266
  • 180 Medical, Inc.$173
  • Tolmar, Inc.$154
  • plus $642 from 14 others

What the payments were for

  • Food & beverage$2,77690%
  • Education$30010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,076 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,938
Medicare patients
170
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide35$502,225
OrgovyxRelugolix76$201,568
Abiraterone Acetate26$133,000
XgevaDenosumab25$74,510
GemtesaVibegron76$61,089
MyrbetriqMirabegron86$59,434
EligardLeuprolide Acetate13$18,576
Tamsulosin Hcl290$4,044
Finasteride214$2,708
Silodosin22$1,416
Solifenacin Succinate17$1,397
Estradiol18$1,091
Alfuzosin Hcl ErAlfuzosin Hcl25$544
Dutasteride12$509
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$285$561,658121 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$584$262,656152 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$122$133,00026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Darby

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →